StockUS listing USIONSNASDAQHealthcareProfitless Growth

Ionis Pharmaceuticals Inc(IONS) Stock Analysis | Healthcare

USD --+0.00%
Reward51Moderate
Risk44Moderate
75%Data
Thin -57% profit margin · Revenue growing 55% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 4.43Bn
Reward Ratingⓘ51 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ44 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on IONS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Ionis Pharmaceuticals Inc?

, a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.

AI Brief Pro

The brief on Ionis Pharmaceuticals Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Ionis Pharmaceuticals Inc?

, a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.43B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (51)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.404
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
21,410 shares
$61k
15,000 shares
$148k
3-6months
15201,312 shares
$16.1M
220,000 shares
$1.1M
6-9months
0
0
9-12months
0
0